Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.

Abstract

The third-generation aromatase inhibitors, letrozole, anastrozole, and exemestane, have been shown to be effective both as alternatives to tamoxifen in first-line treatment of hormone-sensitive advanced breast cancer in postmenopausal women and following failure of first-line tamoxifen for endocrine therapy. These 3 agents are now being investigated as adjuvant therapy of early breast cancer, as alternative or complementary treatments to the standard, tamoxifen. Three treatment strategies are under investigation: replacement of tamoxifen as adjuvant therapy for 5 years (early adjuvant therapy), sequencing of tamoxifen before or after an aromatase inhibitor during the first 5 years (early sequential adjuvant therapy), or following 5 years of tamoxifen (extended adjuvant therapy). In the first adjuvant trial (Arimidex, Tamoxifen Alone or in Combination [ATAC]), anastrozole was significantly superior to tamoxifen in reducing risk of disease recurrence, and recently, the Breast International Group (BIG) trial BIG 1-98 demonstrated the significant superiority of letrozole over tamoxifen in improving disease-free survival. A large trial (International Collaborative Cancer Group [ICCG] trial 96) investigated sequencing of 2 to 3 years of exemestane after 2 to 3 years of tamoxifen and found that switching to exemestane was significantly superior in disease-free survival compared with continuing on tamoxifen. The Arimidex or Nolvadex (ARNO) and the small ITA (Italian Tamoxifen Arimidex) trials similarly sequenced anastrozole after tamoxifen and also found that sequencing reduced the hazard of recurrence compared with remaining on tamoxifen. Trial MA.17 evaluated extended adjuvant therapy with letrozole vs placebo following 5 years of tamoxifen. Disease-free survival was significantly improved with letrozole vs placebo, irrespective of whether patients had lymph node-positive or node-negative tumors. All 3 aromatase inhibitors were generally well tolerated. Results of these trials indicate that aromatase inhibitors provide important benefits relative to tamoxifen in each of these adjuvant treatment settings, but the optimal approach still needs to be defined. Other trials continue to investigate some of these adjuvant treatment strategies.

• Authors: Henning T Mouridsen, Nicholas J Robert
• Journal: MedGenMed : Medscape general medicine (MedGenMed) Vol. 7 Issue 3 Pg. 20 (Aug 24 2005) ISSN: 1531-0132 [Electronic] United States
• PMID: 16369246 (Publication Type: Journal Article, Review)

Chemical References

• Androstadienes
• Aromatase Inhibitors
• Nitriles
• Triazoles
• Anastrozole
• Letrozole
• exemestane

Topics

• Anastrozole
• Androstadienes (therapeutic use)
• Aromatase Inhibitors (therapeutic use)
• Breast Neoplasms (drug therapy)
• Chemotherapy, Adjuvant
• Clinical Trials as Topic
• Female
• Humans
• Letrozole
• Nitriles (therapeutic use)
• Postmenopause
• Triazoles (therapeutic use)